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The transition of ductal carcinoma in situ (DCIS) to invasive carcinoma (IC) in breast
cancer can be faithfully reproduced by the intraductal mouse model. Envisaging to
use this model for therapeutic testing, we aimed to in-depth characterize the tumor
immunity associated with the differential progression of two types of intraductal tumors.
More specifically, we focused on triple-negative breast cancer (TNBC) and intraductally
inoculated luciferase-expressing metastatic 4T1 and locally invasive Py230 cells in
lactating mammary glands of syngeneic BALB/c and C57BL/6 female mice, respectively.
Although the aggressive 4T1 cells rapidly formed solid tumors, Py230 tumors eventually
grew to a similar size through enhanced proliferation. Yet, ductal tumor cell breakthrough
and metastasis occurred earlier in the 4T1- compared to the Py230-based intraductal
model and was associated with high expression of matrix metalloproteinase (MMP)-9,
vascular endothelial growth factor (VEGF), chitinase 3-like 1 (CHI3L1) and lipocalin 2
(LCN2) as well as an increased influx of immune cells (mainly macrophages, neutrophils
and T-cells). Moreover, activated cytotoxic T-cells, B-cells and programmed death-1
(PD-1)-positive cells were more prominent in the 4T1-based intraductal model in line
with enhanced pro-inflammatory cytokine and gene expression profiles. Py230-based
tumors showed a more immunosuppressed anti-inflammatory profile with a high amount
of regulatory T-cells, which may account for the decreased T-cell activation but increased
proliferation compared to the 4T1-based tumors. Taken together, our results highlight
the differential immunological aspects of aggressive metastatic and non-aggressive
intraductal progression of 4T1- vs. Py230-based tumors, providing a base for future
studies to explore therapy using these intraductal TNBC models.
Keywords: triple-negative breast cancer, intraductal model, 4T1 mammary tumor cells, Py230 mammary tumor
cells, tumor immunology
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INTRODUCTION
Breast cancer is the most frequently diagnosed and deadly
cancer in women (1). At the initial stage, breast tumors typically
remain inside the mammary ducts (i.e., ductal carcinoma in situ,
DCIS), but then may quickly become invasive in the surrounding
fat tissue and metastasize to distant organs. Although the
immune system is primed to attack tumor cells during this
disease process, it mostly fails to stop the overall breast tumor
progression. It stands for reason that immunotherapy, that aims
at restoring the anti-tumor immune response, may be effective
in quenching breast cancer (2). Mouse models that replicate
human breast cancer play an essential role in the preclinical
screening of such drugs. To this end, we and others have
shown that inoculation of mammary tumor cells in the murine
mammary ductal environment, also referred to as the mouse
intraductal (MIND) model, provides a significant advantage
over the classical fat pad model as it allows to monitor disease
progression from early DCIS to invasive carcinoma (IC) (3–10).
Recently, we at first identified the stimulatory role of macrophage
polarization in ductal breakthrough and metastatic progression
in triple-negative breast cancer (TNBC) using a model based
on intraductal inoculation of 4T1 mammary tumor cells in
syngeneic BALB/cmice, suggesting that macrophage polarization
is a potential immunotherapeutic target (4). Nevertheless, a more
thorough knowledge of tumor immunological processes during
the in situ, invasive and metastatic phases of breast cancer
development is warranted to further validate this innovative
intraductal model as a screening tool for therapy.
In the current study, we characterized the immune landscape
within the intraductal model, focusing on TNBC. More
specifically, we intraductally inoculated and compared the
growth and tumor immunology of the aggressive BALB/c-
derived 4T1 cell line vs. the slowly growing C57BL/6-derived
Py230 cell line both in a syngeneic background. We here identify
that Py230 tumor cells are able to catch up with 4T1 tumors by 6
weeks (w) post-inoculation (p.i.) through an enhanced cellular
proliferation, but show no systemic advancement at that time.
As tumor cells invaded through the ductal barrier, the tumor
microenvironment significantly changed and showed increased
immune cell influx. The different tumor outgrowth was also
associated with a differential tumor immunology as 4T1 primary
tumors were more pro-inflammatory showing high amounts of
activated cytotoxic T-cells and immune-stimulating cytokines,
and Py230 primary tumors were more anti-inflammatory
containing a high number of regulatory T-cells, weak cytotoxic
T-cell activation, and increased immunosuppressive cytokines.
Taken together, the 4T1- and Py230-based intraductal model
represent a different type of TNBC outgrowth and immune
microenvironment that can be explored as preclinical tool for
testing therapeutic strategies.
MATERIALS AND METHODS
Mice
Wild-type BALB/c and C57BL/6 mice were purchased from
Envigo. Albino NF-κB luc/Tyr−/− C57BL/6 mice, which carry
a heterozygous nuclear factor-kappa B (NF-κB) luc transgene
and lack the tyrosinase-expressing gene responsible for coat
color, were a kind gift from Harald Carlsen (11). No genetic
drift was observed during the period of the study based on
a 384 single nucleotide polymorphism (SNP) panel performed
by Charles River Genetic Testing Services. Animals were
conventionally housed with access to food and water ad libitum.
All animal research was conducted in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and
approved by the Committee on the Ethics of Animal Experiments
of The Faculty of Veterinary Medicine at Ghent University
(approval numbers: EC2015/127, EC2016/56, and EC2017/80).
4T1 and Py230 Cell Culture
BALB/c-derived 4T1 mammary tumor cells constitutively
expressing firefly luciferase were a kind gift from Prof.
Clare Isacke (Breakthrough Breast Cancer Research Centre,
London, UK). These cells resemble the aggressive metastatic
characteristics of human TNBC [lacking expression of estrogen
receptor (ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2)] (12, 13). Py230 mammary
tumor cells were purchased from the American Type Culture
Collection (ATCC). These cells were originally derived from
spontaneous tumors in MMTV-PyMT transgenic mice with
a C57BL/6 background and have been used to model TNBC
(14). Cell lines were maintained at 37◦C and 5% CO2 in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin and 100µg/ml streptomycin (Thermo Fisher Scientific,
Waltham, MA, USA) for 4T1 cells and Ham’s F-12K (Kaighn’s)
Medium (Thermo Fisher Scientific) supplemented with 0.1%
MITO+ Serum Extender (Corning), 5% heat-inactivated FBS,
100 U/ml penicillin and 100µg/ml streptomycin (Thermo Fisher
Scientific) for Py230 cells. Cultured cells were harvested using
0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) (Thermo
Fisher Scientific), washed through centrifugation (805 g for
5min) and resuspended in phosphate buffered saline (PBS)
(Thermo Fisher Scientific). A Bürcker chamber was used to count
the number of harvested cells.
Intraductal Tumor Cell Inoculation
Lactating female mice were intraductally inoculated in the third
mammary gland with either 5 × 104 4T1 or 1 × 105 Py230
mammary tumor cells under inhalation anesthesia (mixture of 2–
3% isoflurane and oxygen). To become lactating, 8-w-old female
and male mice were mated and pups were weaned 10 days
after delivery. 4T1 and Py230 cells suspended in a mixture of
1:10 PBS and Matrigel R© were inoculated through the mammary
teat canal 1 h after weaning using a 32-gauge blunt needle
in a BALB/c and C57BL/6 background, respectively, to obtain
immunocompetent models.
Analysis of Primary Tumor Growth and
Metastases
4T1 and Py230 primary tumor volumes were analyzed weekly as
a measurement of primary tumor growth using a digital caliper.
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The growth of 4T1 primary tumors was also monitored by
imaging 4T1-derived bioluminescence at the primary tumor site.
Bioluminescence in the Py230 intraductally inoculated NF-κB
luciferase reporter mice was monitored at the primary tumor site
as a measurement of NF-κB activity and inflammation in primary
tumors. To acquire the images, mice were intraperitoneally (i.p.)
injected with 200 µl D-luciferin in PBS (at a concentration of
2 mg/100 µl, Gold Biotechnology, St. Louis, MO) and placed
in an IVIS lumina II system (PerkinElmer, Zaventem, Belgium)
approximately 10min later under inhalation anesthesia. 4T1-
derived bioluminescence in axillary lymph node, lung and liver
metastases as well as NF-κB-derived bioluminescence in axillary
lymph nodes were acquired through ex vivo imaging. Therefore,
mice were i.p. injected with a mixture of 100 mg/kg ketamine
(Ketamidor, Ecuphar nv/sa, Oostkamp, Belgium) and 10 mg/kg
xylazine (Xylazini Hydrochloridum, Val d’Hony-Verdifarm,
Beringen, Belgium) for sedation and sacrificed through cervical
dislocation. Organs were subsequently isolated and screened
for bioluminescence. Spleens were also isolated and weighed.
Bioluminescence signals were quantified by dividing the total flux
with the selected area using living image analysis software 3.2.
Flow Cytometric Immunophenotyping of
Primary Tumor Immune Populations
4T1 and Py230 primary tumors were isolated from intraductally
inoculated mice following scarification. To obtain a single cell
suspension, primary tumors were chopped into small fragments
and transferred into a gentleMACSCTube containing an enzyme
mix of 2.35ml RPMI 1640 (Thermo Fisher Scientific), 100 µl
Enzyme D, 50 µl Enzyme R and 12.5 µl Enzyme A (enzymes
derived from a commercially available Tumor dissociation kit
from Miltenyi Biotec, Leiden, The Netherlands). The C Tubes
were attached onto a gentleMACS Dissociator, subjected to the
gentleMACS Program m_impTumor_02 for 37 s and incubated
for 40min at 37◦C with continuous rotation at 40 rpm for
optimal enzymatic digestion. The C Tubes were then subjected
to the gentleMACS Program m_impTumor_03 twice for 37 s,
after which the cell suspensions were allowed to settle and run
on the m_impTumor_01 for 60 s to increase the cell yield. Cells
were pelleted through a short spin up to 300 g and applied to a
70µm cell strainer. Washing of the cell strainer with 10ml of
RPMI 1640, pelleting of the cells through centrifugation at 800 g
for 7min and resuspension of the cells into 1ml of RPMI 1640
created a final cell suspension that was used for further analysis.
Cells were counted on a flow cytometer (Cytoflex, Analis,
Ghent, Belgium) by bringing 100µl of the final cell suspension in
a well of a 96 well plate. Cellular viability was also evaluated in this
well by adding 2µl propidium iodide (PI, 50µg/ml) to the 100µl
suspension. The remaining 900µl of the final cell suspension was
pelleted at 800 g for 7min and dissolved at a concentration of 2×
106 cells/ml in FcR blocking reagent diluted 1:10 in FACS buffer
(PBS with 1% bovine serum albumin (BSA), 2.5mM EDTA, and
0.01% sodium azide). For staining of the cells, 100 µl of the
mixture (corresponding with 2 × 105 cells) was brought in each
well of a 96 well plate, cells were pelleted at 800 g for 5min and
incubated for 30min at 4◦C in a 100 µl cocktail of antibodies
supplemented in FACS buffer. Following antibodies and dilutions
were used: anti-CD45-biotin (1:200, clone 30-F11, Thermo Fisher
Scientific), anti-F4/80-APC (1:20, clone CI:A3-1, Bio-Rad, CA,
USA), anti-Ly6G-APC (1:10, clone 1A8, Miltenyi Biotec), anti-
CD3ε-FITC (1:50, clone 145-2C11, BioLegend, CA, USA), anti-
CD4-PE (1:80, clone GK1.5, BioLegend), anti-CD8a-APC (1:80,
clone 53-6.7, BioLegend). Staining with secondary streptavidin-
PE (1:333, Thermo Fisher Scientific) or streptavidin-eFluor 450
(1:80, Thermo Fisher Scientific) was performed to detect anti-
CD45-biotin. Therefore, cells were pelleted again at 800 g for
5min, washed with FACS buffer and incubated for 30min at
4◦C in 100 µl of streptavidin antibody supplemented in FACS
buffer. Isotype-matched and auto-fluorescence controls were
used for identification and quantification of staining positivity.
After the cellular stainings, cells were pelleted again at 800 g for
5min, washed twice with FACS buffer and analyzed with a flow
cytometer. All acquired data were processed using CytExpert
v2.0.0.153 software (Beckman Coulter, Inc., California, USA).
Compensation for spectral overlap between fluorochromes was
performed using an automatic calibration technique of the
software and subsequently evaluated individually with a matrix.
Histology and Immunohistochemistry
Tissues were isolated, fixed for 24 h at room temperature (RT)
in 3.5% buffered formaldehyde and embedded in paraffin.
Tissue sections of 5µm were deparaffinized, rehydrated and
then stained with hematoxylin and eosin (H&E). Following
dehydration, tissue sections were mounted with a cover glass for
further analysis.
Immunohistochemical stainings relied on antigen retrieval of
deparaffinized 2–3µm thick tissue sections with citrate buffer
[pH 6, 10mM tri-sodium citrate (Santa Cruz Biotechnology,
Heidelberg, Germany); for Ki67, CD31, carbonic anhydrase 9
(CAIX), CD45, CD163, CD11c Ly6G, CD3ε, CD8a, CD4, FoxP3,
granzyme B, programmed death-1 (PD-1), and CD19], or Tris-
EDTA buffer [pH 9, 10mM Tris, 1mM EDTA (Thermo Fisher
Scientific); for cytokeratin 5] supplemented with 0.05% Tween-
20 (Sigma-Aldrich, Bornem, Belgium) at 95◦C for 30min under
pressure in a Decloaking Chamber NxGen (Biocare Medical,
CA, USA). After cooling down to RT for 30min, slides were
incubated in a microscope slide box with tris-buffered saline
(TBS)-wetted paper at 20 rpm on an orbital shaker for further
incubation steps. 0.6%H2O2 inmethanol (for CD8a) or 3%H2O2
in methanol (all other targets) was applied on the sections for
10min as an endogenous peroxidase block, followed by serum-
free protein block for 10min. Primary antibodies were diluted
in Antibody diluent (Dako) and applied for 1 h at RT. Following
primary antibodies and dilutions were used: anti-cytokeratin
5 (1:100, clone EP1601Y, Abcam, Cambridge, UK) anti-Ki67
(1:50, clone SP6, Thermo Fisher Scientific), anti-CD31 (1:2000,
clone EPR17259, Abcam), anti-CAIX (1:1000, clone NB100-
417, Novus Biologicals, Littleton, CO, USA), anti-CD45 (1:1000,
clone 30-F11, Thermo Fisher Scientific), anti-CD163 (1:500,
clone EPR19518, Abcam), anti-CD11c (1:100, clone D1V9Y,
Cell Signaling Technology, Leiden, The Netherlands), anti-
Ly6G (1:1000, clone 1A8, BioLegend), anti-CD3ε (1:1000, clone
EPR20752, Abcam), anti-CD8a (1:50, clone 4SM15, Thermo
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Fisher Scientific), anti-CD4 (1:1000, clone 4SM95, Thermo Fisher
Scientific), anti-FoxP3 (1:100, clone FJK-16s, Thermo Fisher
Scientific), anti-granzyme B (1:1000, polyclonal, Abcam), anti-
PD-1 (1:1000, clone EPR20665, Abcam) and anti-CD19 (1:1000,
clone 6OMP31, Thermo Fisher Scientific). Secondary antibodies
were subsequently applied for 30min at RT. Following secondary
antibodies were used: Rat-on-mouse HRP-Polymer (Biocare
Medical) for CD45, Ly6G, CD8a, CD4, FoxP3, and CD19, and
Dako EnVision+ Rabbit (Dako) for cytokeratin 5, Ki67, CD31,
CAIX, CD163, CD11c, CD3ε, granzyme B, and PD-1. To detect
positive staining, sections were treated with a buffer containing
3,3
′
-diaminobenzidine (DAB) for 10min at RT. Counterstaining
was performed by applying hematoxylin for 5min. Rinsing of the
slides between all incubations relied on TBS applied 3 times for
2min. For quantification of the stainings, color deconvolution
and automatic counting was applied through ImageJ. Ki67
proliferation indices were determined using ImageJS (15).
Analysis of Cytokine and Protein Levels
To extract proteins, isolated primary tumors and spleens were
homogenized and lysed with lysis buffer supplemented with
protease inhibitors [1% Nonidet P-40, 10mM Tris-HCl at
pH 7.4, 200mM NaCl, 5mM EDTA, 10% glycerol, 100µM
phenylmethylsulfonyl (PMSF), 1mM oxidized L-glutathione (all
from Sigma-Aldrich), 0.15µM aprotinin and 2.1µM leupeptin
(Roche, Mannheim, Germany)] as previously described (4).
Serum was derived from blood which was collected through
cardiac puncture, allowed to clot at 37◦C for 30min and
centrifuged at 17,000 g for 1 h at 4◦C. The levels of 10 selected
cytokines (BAFF, G-CSF, IFN-γ, IL-1β, IL-4, IL-6, IL-10, MCP-1,
MIP-2, and TNF-α) were measured through Luminex Multiplex
Assays (Thermo Fisher Scientific) in primary tumor lysates
(50 µg of protein) and sera (1:4 diluted in assay diluent).
Enzyme-linked immunosorbent assay (ELISA) was used to
measure CHI3L1 and LCN2 levels (MouseQuantikine ELISAKit,
Biotechne, Minneapolis, MN, USA) in primary tumor lysates,
sera and spleen lysates, and the levels of MMP-9, VEGF (Mouse
Quantikine ELISA Kit, Biotechne) and TGF-β1 (Mouse uncoated
ELISA Kit, Thermo Fisher Scientific) in primary tumor lysates
and sera with absorbances at 550 nm subtracted from those at
450 nm for correction. ELISA data were analyzed by means of
Deltasoft JV (BioMetallics Incorporated).
RNA-Seq Analysis
RNA was isolated from 4T1 and Py230 tumors at 3 different time
points (i.e., 1, 3, and 6w p.i.) using in house developed protocols
(16). All analyses were done in triplicate. In addition, Matrigel R©
controls were included for each intraductal model and time
point, yielding a total of 36 samples. RNA quality and quantity
were analyzed using the Agilent BioAnalyzer and the NanoDrop,
respectively, according the manufacturer’s instructions. RNA
sequencing was done in collaboration with Oxford Genomics
using Illumina’s TruSeq chemistry. Briefly, 100 ng of total
RNA was subjected to a stranded library preparation, and
libraries were sequenced (i.e., paired-end; read length of 75
bp) on a HiSeq4000 using 2 lanes aiming for 10 million reads
per sample. This allows accurate assessment of the expression
levels of the 50% most strongly expressed genes (coefficient
of variation between 10 replicates inferior to 5%), which
corresponds to genes having at least 10 associated reads in the
respective libraries. Reads were mapped to the mouse reference
genome (mm10) using STAR. Read counts were generated
using the summariseOverlaps function from the BioConductor
package GenomicAlignments. Raw counts were normalized and
analyzed for differential expression using the DESeq2 package
in BioConductor. Regression models were set up to allow
evaluation of expression differences between the 4T1- and Py230-
based intraductal model at each time point and plain time
effects were accounted for using the Matrigel R© control samples.
Significant differences were considered when nominal P-values
were inferior to 5%. Lists of differentially expressed genes were
translated into biological concepts (i.e., hallmark category of
the molecular signatures database from the Broad Institute)
using gene set enrichment analysis (GSEA). Therefore, mouse
gene symbols were first translated into their human homologs
using the getLDS function from the biomaRt package in
BioConductor. Heatmaps in Figures 10, 11 were generated using
the online tool Heatmapper (17) and in Supplementary Figure 5
using R.
Statistical Analysis
Analysis of Variance (ANOVA) tests with Tukey’s post-hoc
tests and unpaired Student’s t-tests were performed using
Prism (GraphPad) to calculate P-values and determine statistical
significant differences (P < 0.05). Log10 normalization was
performed to normalize data when necessary.
RESULTS
DCIS to IC Progression Is More Aggressive
in the 4T1- Compared to the Py230-Based
Intraductal Model as Reflected by Local
and Systemic Disease Markers
To establish the immunocompetent 4T1- and Py230-based
intraductal model, BALB/c-derived 4T1 mammary tumor cells
and C57BL/6-derived Py230 mammary tumor cells were
intraductally inoculated in lactating syngeneic mice. Primary
tumor volume measurements indicated that 4T1 cells grew
more aggressively than Py230 cells inside the mammary glands
and established larger primary tumors between 1 and 5w
p.i. (Figure 1A). In contrast, Py230 cells grew exponentially
and at 6w p.i. the Py230 and 4T1 primary tumor volumes
no longer differed (Figure 1A). As the 4T1 tumor cells were
luminescently traceable, in vivo imaging allowed to verify
their invasive primary tumor growth and showed that they
expanded across the mammary gland and the surrounding
tissue (Supplementary Figure 1A). H&E histology of primary
tumors at 1, 3, and 6w p.i. confirmed DCIS to IC progression
in both the 4T1- and Py230-based intraductal model, with
4T1 cells displaying both enhanced and earlier invasion at
3w p.i. (Figure 1B). Corroborating this key finding, increased
disruption of the myoepithelial cell layer by 4T1 cells at 3 w
p.i. was verified based on decreased cytokeratin 5 positivity
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FIGURE 1 | Tumor growth, ductal breakthrough and tumor proliferation in the 4T1- compared to Py230-based intraductal model. 4T1 and Py230 mammary tumor
cells were intraductally inoculated in syngeneic lactating dams and primary tumor progression was monitored. (A) Weekly primary tumor volume measurements up to
6w p.i. (4T1 primary tumors: n = 52 at 1w p.i., n = 36 at 2 and 3w p.i., n = 18 at 4, 5, and 6w p.i.; Py230 primary tumors: n = 43 at 1w p.i., n = 33 at 2 and 3w
p.i., n = 23 at 4 and 5w p.i., n = 29 at 6w p.i.). (B) H&E histology of Py230 and 4T1 primary tumors at 1, 3, and 6w p.i. Scale bars = 50µm. Data in (A) are
presented as the means ± standard error of the mean (SEM). NS, not significant. **P < 0.01, ***P < 0.001.
FIGURE 2 | Ductal breakthrough and tumor proliferation in the 4T1- compared to Py230-based intraductal model. Immunohistochemistry for the myoepithelial cell
marker cytokeratin 5 and cell proliferation marker Ki67 on sections of Py230 and 4T1 primary tumors at 1, 3, and 6w p.i. (n = 5 at each time point for both 4T1 and
Py230 primary tumors). A Ki67 proliferation index was determined of Py230 and 4T1 primary tumors at 1, 3, and 6w p.i. by calculating the fraction of Ki67+ nuclei
among all nuclei using ImageJS (15). All nuclei are marked in blue and Ki67+ nuclei are marked in red. Scale bars = 50µm. Data are presented as the means ± SEM.
NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001.
in 4T1 compared to Py230 primary tumors (Figure 2). Ki67
staining confirmed the increased tumor cell proliferation in
4T1 compared to Py230 primary tumors at 1 w p.i., but
not at 3 and 6w p.i. (Figure 2). Moreover, calculation of
the Ki67 proliferation index (i.e., the percentage of Ki67
stained nuclei relative to all nuclei in the primary tumor)
showed that, in marked contrast to the index at 1w p.i.,
Py230 primary tumors were more proliferative than 4T1
primary tumors by 3w p.i. (Figure 2), supporting the earlier
finding that Py230 tumors are able to catch up with 4T1
tumor growth.
Additionally, distant metastases in the 4T1- and Py230-based
intraductal model were investigated at 6w p.i. by H&E histology
and ex vivo imaging. H&E histology showed metastases in
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axillary lymph nodes, lungs and liver from 4T1, but not from
Py230 tumor-bearing mice (Supplementary Figure 1B). Ex vivo
imaging confirmed the presence of 4T1-derived bioluminescence
in these three organs (Supplementary Figure 1B). MMP-9
and VEGF, proteins that are important for tumor metastasis
through extracellular matrix degradation and angiogenesis,
respectively, were measured locally in primary tumors and
systemically in serum, identifying increased MMP-9 levels at
1, 3, and 6w p.i. (Figure 3A) and increased VEGF levels
at 3 as well as 6 w p.i. (Figure 3B) in the 4T1- compared
to the Py230-based intraductal model. However, MMP-9 and
VEGF levels in primary tumors and serum did not increase
to the same extent. The fold induction of the mean MMP-
9 and VEGF levels in the 4T1- compared to the Py230-
based model showed remarkable differences in primary tumors
(Supplementary Figures 2A,B). More specifically, MMP-9 was
more strongly induced at 1w p.i. compared to VEGF, whereas
at 3 w p.i. VEGF was more strongly induced compared to MMP-
9 (Supplementary Figures 2A,B). At 6w p.i., MMP-9 was again
more strongly induced compared to VEGF, albeit to a lesser
extent than at 1w p.i. (Supplementary Figures 2A,B). In serum,
the fold induction of MMP-9 in the 4T1- compared to the Py230-
based model was only clearly higher compared to that of VEGF
at 6w p.i. (Supplementary Figures 2A,C). CD31 stainings in
primary tumors corroborated the increased angiogenesis at 3
and 6w p.i. in the 4T1-based intraductal model (Figure 3C).
However, based on stainings for the hypoxia marker CAIX
(18, 19) the increased angiogenesis did not result in a decrease
of hypoxia. More specifically, 4T1 primary tumors showed a
progressive increase in CAIX positivity from 1 to 6w p.i., whereas
the slower progressing Py230 primary tumors showed fewer
CAIX staining (Figure 3C). The increased tumor progression
in the 4T1-based intraductal model was accompanied with a
more progressive splenomegaly compared to the Py230-based
intraductal model based on spleen weight measurements at 1,
3, and 6w p.i. (Figures 4A,B), indicative for enhanced systemic
disease as well as leukemoid reactions (20, 21). Two immuno-
oncological biomarkers for disease monitoring in mice (3, 4) and
breast cancer patients (22–24), CHI3L1 and LCN2, corroborated
the 4T1 disease progression and showed significantly increased
levels in 4T1 compared to Py230 primary tumors at 1 and
3w p.i., but not at 6 w p.i. (Figure 4C), when 4T1 and Py230
primary tumors reached similar volumes. In serum, on the
other hand, CHI3L1 and LCN2 were significantly increased
at 1, 3, and 6w p.i. in the 4T1- compared to the Py230-
based intraductal model (Figure 4D), reflecting the enhanced
metastatic progression of 4T1 tumor cells following intraductal
inoculation. CHI3L1 and LCN2 levels in spleens corroborated the
increased splenomegaly at 3 and 6w p.i. in the 4T1- compared
to the Py230-based intraductal model (Figure 4E) and further
indicated the presence of enhanced leukocyte reactions in the 4T1
tumor-bearing mice.
FIGURE 3 | MMP-9 and VEGF levels, tumor vascularity and hypoxia in the 4T1- compared to Py230-based intraductal model. Primary tumor and serum MMP-9 (A)
and VEGF (B) levels at 1, 3, and 6w p.i. in the 4T1- and Py230-based intraductal model (4T1-based model: n = 7 tumors and 10 sera at 1w p.i., n = 7 tumors and 9
sera at 3w p.i., n = 8 tumors and 9 sera at 6w p.i.; Py230-based model: n = 7 tumors and 10 sera at 1w p.i., n = 5 tumors and 7 sera at 3w p.i., n = 11 tumors and
7 sera at 6w p.i.). (C) Immunohistochemistry for the endothelial cell marker CD31 and hypoxia marker CAIX on sections of 4T1 and Py230 primary tumors at 1, 3, and
6w p.i. (n = 5 at each time point for both 4T1 and Py230 primary tumors). Scale bars = 50µm. Data are presented as the means ± SEM. NS, not significant.
*P < 0.05, **P < 0.01, ***P < 0.001.
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FIGURE 4 | Splenomegaly and levels of immune-related disease biomarkers CHI3L1 and LCN2 in the 4T1- compared to Py230-based intraductal model.
(A) Representative images of spleens isolated from the 4T1- and Py230-based intraductal model at 1, 3, and 6w p.i. The image of a spleen from a normal mouse is
also shown for comparison. (B) Weight measurements of spleens isolated from the 4T1- and Py230-based intraductal model at 1, 3, and 6w p.i. (n = 9 spleens at
each time point for both the 4T1- and Py230-based model). The dotted line indicates the mean spleen weight of 6 normal mice. (C–E) CHI3L1 and LCN2 levels at 1,
3, and 6w p.i. in primary tumors (C), sera (D), and spleens (E) of the 4T1- and Py230-based intraductal model (4T1-based model: n = 6 tumors, 8 sera, and 5
spleens at 1w p.i., n = 7 tumors, 8 sera, and 5 spleens at 3w p.i., n = 8 tumors, 8 sera, and 6 spleens at 6w p.i.; Py230-based model: n = 7 tumors, 9 sera, and 5
spleens at 1w p.i., n = 5 tumors, 7 sera, and 5 spleens at 3w p.i., n = 11 tumors, 7 sera, and 5 spleens at 6w p.i.). Data in (B–E) are presented as the means ±
SEM. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001.
DCIS to IC Progression Is Accompanied by
an Increase in Immune Cells That Occurs
Earlier in the 4T1- Compared to the
Py230-Based Intraductal Model
The immune system plays a pivotal role in the progression of
mammary tumors. Moreover, their invasiveness is associated
with immune cell changes in the tumor microenvironment
(25, 26). In order to investigate the primary tumor immune
cell populations upon DCIS to IC progression in the 4T1-
and Py230-based intraductal model, isolated primary tumors
from both these models at 1, 3 and 6w p.i. were processed
into single cells and immunophenotyped by flow cytometry
(Figure 5A). Based on the pan-immune cell marker CD45,
the number of leukocytes increased over time in the 4T1 as
well as the Py230 primary tumors (Figure 5B). However, at 1
and 3w p.i. a significantly higher number of CD45+ immune
cells was detected in 4T1 compared to Py230 primary tumors,
indicative for a substantially more enriched tumor immune
microenvironment in the 4T1-based intraductal model at these
early time points (Figure 5B). In accordance with the higher
percentage of CD45+ immune cells, 4T1 primary tumors showed
significantly increased percentages of the F4/80+ (Figure 5C),
Ly6G+ (Figure 5D), and CD3ε+ (Figure 5E) immune cell types
at 1 and 3w p.i. compared to Py230 primary tumors. When
the CD3ε+ T-cell population was subdivided into CD4+ T-
helper cells and CD8a+ cytotoxic T-cells, an increase in the
CD8a/CD4 T-cell ratio was found in 4T1 as well as Py230 primary
tumors between 1 and 6w p.i. (Figures 5A,F). Consequently,
DCIS to IC progression is associated with a switch from a
high number of T-helper cells to a high number of cytotoxic
T-cells in the primary tumor microenvironment. However, the
significantly increased CD8a/CD4 T-cell ratio at 3 w p.i. in 4T1
compared to Py230 primary tumors indicates that this switch
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FIGURE 5 | Flow cytometric immunophenotyping of tumor immune populations in the 4T1- compared to Py230-based intraductal model. Primary tumors were
isolated from the 4T1- and Py230-based intraductal model at 1, 3, and 6w p.i. and dissociated into a single cell suspension. Distinct immune cell types in the single
cell suspension were quantified by flow cytometry. (A) Gating strategy for analysis of single cells and expression of CD45, F4/80, Ly6G, CD3ε, CD8a, and CD4. (B–F)
Positivity for CD45 (pan-immune cells) as a percentage of total single cells (B), positivity for F4/80 (macrophages) (C), Ly6G (neutrophils) (D), and CD3ε (T-cells) (E) as
a percentage of CD45+ cells, and the ratio of CD8a+ cells (cytotoxic T-cells) and CD4+ cells (T-helper cells) (F) at 1, 3, and 6w p.i. in primary tumors isolated from the
4T1- and Py230-based intraductal model (4T1 primary tumors: n = 4 at each time point; Py230 primary tumors: n = 4 at 1w p.i., n = 3 at 3 and 6w p.i.). F4/80+,
Ly6G+, and CD3ε+ fraction of total leukocytes in Py230 (G) and 4T1 (H) primary tumors at 1, 3, and 6w p.i. Data in (B–F) are presented as the means ± SEM, data in
(G,H) are presented as the means. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001.
occurs earlier in the 4T1-based intraductal model. Investigation
of the changes in proportion of immune cells over time in the
4T1- and Py230-based intraductal model showed that F4/80+
macrophages were the most abundant immune cell type at 1 and
3w p.i., and that Ly6G+ neutrophils and CD3ε+ T-cells caught
up with the macrophage numbers by 6w p.i. (Figures 5G,H).
More specifically, in 4T1 primary tumors, each of these three
immune cell types comprised about 30% of the total immune cells
at this end point, together approximating 90% of the primary
tumor immunophenotype (Figure 5G). In marked contrast, in
the Py230-based primary tumors, F4/80+macrophages remained
the predominant immune cell type (34%) at 6w p.i., although
closely followed in numbers by Ly6G+ neutrophils (16%) and
CD3ε+ T-cells (24%), together approximating 75% of the primary
tumor immunophenotype (Figure 5H).
Immunohistochemical CD45 stainings corroborated the
immunophenotyping by identifying an increased number of
immune cells over time in the tumor stroma, but also immune
cells infiltrating into the tumor tissue at 3 and 6w p.i. (Figure 6),
when tumor cells became invasive. The 4T1 primary tumors
showed significantly increased CD45 positivity at 1 and 3w
p.i. and equal CD45 positivity at 6 w p.i. compared to Py230
primary tumors. Similarly, CD163 stainings demonstrated a
progressive increase of tumor-associated macrophages (TAMs)
in the surrounding primary tumor stroma, with 4T1 primary
tumors showing significantly higher CD163 positivity at 1 and
3w p.i., but not at 6 w p.i. compared to Py230 primary tumors
(Figure 6). Also CD11c and Ly6G stainings for tumor-associated
dendritic cells (TADCs) and tumor-associated neutrophils
(TANs), respectively, increased over time in primary tumor
sections of both models, with 4T1 primary tumors showing
significantly increased positivity for both markers at 1 and 3w
p.i., but not at 6 w p.i. compared to Py230 primary tumors
(Figure 6). Moreover, whereas Ly6G stainings were located
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FIGURE 6 | Immunohistochemical analysis of innate immune cell populations in primary tumors of the 4T1- compared to Py230-based intraductal model.
Immunohistochemistry for the pan-immune cell marker CD45, the tumor-associated macrophage marker CD163, the dendritic cell marker CD11c and the neutrophil
marker Ly6G on sections of 4T1 and Py230 primary tumors at 1, 3, and 6w p.i. (n = 5 at each time point for both 4T1 and Py230 primary tumors). Dashed inserts
and arrowheads indicate the few Ly6G+ cells at 1w p.i. in both 4T1 and Py230 primary tumors and at 3w p.i. in Py230 primary tumors. Black scale bar = 50µm, red
scale bar = 20µm. Data are presented as the means ± SEM. NS, not significant. *P < 0.05, ***P < 0.001.
within the primary tumor area at all times, CD11c stainings for
TADCs were initially located in the tumor stroma at 1w p.i.
and subsequently invaded the primary tumor core by 3 and 6w
p.i. Regarding the adaptive immune cells, immunohistochemistry
showed significant increase in CD3ε stainings for tumor-
infiltrating lymphocytes (TILs), in CD8a stainings for cytotoxic
T-cells, and in CD4 stainings for T-helper cells in the primary
tumor area of the 4T1- compared to Py230-based model
at 1 and 3w p.i., but not at 6 w p.i. (Figure 7A). FoxP3
stainings for immunosuppressive regulatory T-cells significantly
increased in the Py230 compared to 4T1 primary tumors at
6 w p.i. (Figure 7B).
More Aggressive Tumor Progression in the
4T1- Compared to the Py230-Based
Intraductal Model Is Characterized by an
Enhanced Inflammation and Cytotoxic
T-Cell Activity
Mammary tumor progression is highly influenced by
inflammatory responses derived from activated immune
cells in the tumor microenvironment. This inflammation is
tightly controlled by inflammatory transcription factors such as
NF-κB (27). NF-κB luciferase reporter mice allow to measure
the host NF-κB activation upon tumor progression and visualize
mammary gland inflammation through bioluminescence
imaging (11, 28, 29). Py230 cells were intraductally inoculated
in these reporter mice and weekly monitoring identified that
host NF-κB activity at the primary tumor site exponentially
increased over time, although there was a distinctive signal
only at 6 w p.i. (Supplementary Figures 3A,B). Isolated axillary
lymph nodes from the mice at 6 w p.i. also showed significantly
higher NF-κB-derived luminescence compared to 1 and 3w p.i.
(Supplementary Figures 3C,D), indicative for an increasing
inflammation in response to the advancing primary tumor.
Local and systemic cytokine profiling allowed amore in-depth
investigation into the inflammation in the intraductal model.
4T1 primary tumors showed significantly increased levels of
pro-inflammatory cytokines B-cell activating factor (BAFF),
granulocyte colony-stimulating factor (G-CSF), interferon
(IFN)-γ, interleukin (IL)-1β, monocyte chemoattractant protein
(MCP)-1, macrophage inflammatory protein (MIP)-2, and
transforming growth factor (TGF)-β1 at 1, 3, and 6w p.i.,
and IL-6 and tumor necrosis factor (TNF)-α at 3 and 6w
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FIGURE 7 | Immunohistochemical analysis of adaptive immune cell populations in primary tumors of the 4T1- compared to Py230-based intraductal model.
(A) Immunohistochemistry for the T-cell marker CD3ε, the cytotoxic T-cell marker CD8a and the T-helper cell marker CD4 on sections of 4T1 and Py230 primary
tumors at 1, 3, and 6w p.i. (n = 5 at each time point for both 4T1 and Py230 primary tumors). (B) Immunohistochemistry for the regulatory T-cell marker FoxP3 on
sections of 4T1 and Py230 primary tumors at 6w p.i. (n = 5 at each time point for both 4T1 and Py230 primary tumors). Dashed inserts and arrowheads indicate the
few CD3ε+ and CD8a+ cells at 1w p.i. in both 4T1 and Py230 primary tumors and at 3w p.i. in Py230 primary tumors, the few CD4+ cells at 1, 3, and 6w p.i. in both
4T1 and Py230 primary tumors, and the few FoxP3+ cells at 6w p.i. in 4T1 and Py230 primary tumors. Black scale bar = 50µm, red scale bar = 20µm. Data are
presented as the means ± SEM. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001.
p.i. compared to Py230 primary tumors (Figures 8A–C). In
contrast, IL-4 and IL-10 levels were significantly higher in
Py230 compared to 4T1 primary tumors at all 3 time points
(Figures 8A–C). Analysis of cytokine levels in serum provided
similar results as in primary tumors with significantly higher
BAFF, G-CSF, MCP-1, MIP-2, and TGF-β1 levels at 1, 3, and 6w
p.i. for the 4T1- compared to the Py230-based intraductal model
(Supplementary Figures 4A–C). IFN-γ, IL-6, and TNF-α serum
levels were detectable only at 3 and 6w p.i. and also significantly
increased in the 4T1- compared to the Py230-based intraductal
model (Supplementary Figures 4A–C).
Cytokine production and release is linked to immune cell
activation in the tumor microenvironment, which can be
targeted with immunotherapy. Especially cytotoxic (CD8a+) T-
cells are an important immunotherapeutic target due to their
tumor-killing function. Therefore, comparative evaluation of the
cytotoxic T-cell activity in primary tumors of both intradutcal
models is of major added value before these models can be used
as therapeutic screening tools. Immunohistochemical stainings
for granzyme B and PD-1, both markers for activated cytotoxic
T-cells, showed increased positivity in 4T1 compared to Py230
primary tumors at 1, 3, and 6w p.i. (Figure 8D). The latter key
observation is in accordance with the higher pro-inflammatory
cytokine levels in the 4T1- compared to the Py230-based
intraductal model. CD19 stainings further revealed the presence
and increase of activated B-cells at 3 and 6w p.i. in 4T1, but not
in Py230 primary tumors (Supplementary Figure 4D).
RNA-Seq Verifies Immunological and
Proliferative Changes Upon Tumor
Progression in the 4T1- Compared to the
Py230-Based Intraductal Model
In order to investigate the changes in both intraductal models
upon tumor progression at the genetic level, sequencing was
performed on RNA isolated from snap frozen 4T1 and Py230
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FIGURE 8 | Cytokine levels and immunohistochemical analysis of cytotoxic T-cell activity in primary tumors of the 4T1- compared to Py230-based intraductal model.
Cytokine levels at 1w p.i. (A), 3w p.i. (B), and 6w p.i. (C) in primary tumors of the 4T1- and Py230-based intraductal model (4T1 primary tumors: n = 7 at 1 and 3w
p.i., n = 8 at 6w p.i.; Py230 primary tumors: n = 7 at 1w p.i., n = 5 at 3w p.i., n = 11 at 6w p.i.). (D) Immunohistochemistry for the activated cytotoxic T-cell markers
granzyme B and PD-1 (n = 5 at each time point for both 4T1 and Py230 primary tumors). Dashed inserts and arrowheads indicate the few PD-1+ cells at 1w p.i. in
both 4T1 and Py230 primary tumors and at 3w p.i. in Py230 primary tumors. Black scale bar = 50µm, red scale bar = 20µm. Data are presented as the means ±
SEM. NS, not significant. *P < 0.05, **P < 0.01, ***P < 0.001.
intraductally inoculated primary tumors at 1, 3 and 6w p.i.
The differentially expressed genes in the 4T1 vs. Py230 primary
tumor datasets at the 3 different time points were categorized
into 28 hallmark gene sets using GSEA. Nine hallmarks could
be related to tumor immunology and collectively showed a
decreased expression over time (allograft rejection, complement,
IL2-STAT5 signaling, IL-6-JAK-STAT3 signaling, inflammatory
response, IFN-α response, IFN-γ response, KRAS signaling up,
and TNF-α signaling via NF-κB) (Figure 9). More specifically, all
9 tumor immunology-related gene sets remained upregulated in
4T1 compared to Py230 primary tumors across the 3 time points,
but only significantly at 1 and/or 3w p.i. Other gene sets could
be related to cellular mitosis and tumor progression, including
DNA repair, E2F targets, G2M checkpoint, mitotic spindle,
MTORC1 signaling, MYC targets V1 and spermatogenesis
(Figure 9). Whereas at 1 w p.i. all gene sets were significantly
upregulated, at 3 w p.i. they became significantly downregulated
or showed a strong decrease compared to 1w p.i. in 4T1
compared to Py230 primary tumors, indicative for decreased
tumor proliferation. At 6w p.i., the gene sets went back
to baseline, highlighting the similar tumor size in 4T1 and
Py230 primary tumors. In contrast to the cellular mitosis gene
sets, the hallmark epithelial-mesenchymal transition (EMT)
was significantly upregulated at 3w p.i. in 4T1 compared to
Py230 primary tumors (Figure 9), indicative for metastatic
progression. Gene sets involved in adipose/stromal processes
within the mammary gland (adipogenesis, angiogenesis, bile
acid metabolism, coagulation, fatty acid metabolism, KRAS
signaling dn, myogenesis, UV response dn, WNT-β-catenin
signaling, and xenobiotic metabolism) were downregulated or
weakly expressed at 1w p.i., but became upregulated at 3w
p.i. in 4T1 compared to Py230 primary tumors (Figure 9),
indicating that at the time 4T1 tumor cells were less proliferative
compared to Py230 tumor cells, the surrounding stroma and
fat tissue were more active in the 4T1- compared to the
Py230-based intraductal model. The hallmark androgen response
also showed a significantly upregulated expression in Py230
tumors at 3 and 6w p.i. (Figure 9), indicating that androgen
signaling is important in invasive Py230 tumors. Hierarchical
clustering of the hallmarks in a heatmap with the different
primary tumor samples at the different time points confirmed
that tumor immunology hallmarks are most represented in
4T1 primary tumors, with the highest representation at 1w
p.i., and cellular mitosis hallmarks are most represented
in 4T1 primary tumors at 6 w p.i. and in Py230 primary
tumors at 3 and 6w p.i. (Supplementary Figure 5). Gene
expression of RNA samples derived from Matrigel R©-only
intraductally injected lactating BALB/c and C57BL/6 mice at
1, 3, and 6w p.i. were also included as a control and showed
a strong representation of stromal/adipose-related hallmarks
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FIGURE 9 | Hallmarks associated with differentially expressed genes in primary tumors of the 4T1- compared to Py230-based intraductal model. RNA isolated from
4T1 and Py230 primary tumors at 1, 3, and 6w p.i. was sequenced and differentially expressed genes were categorized into hallmark gene sets using GSEA. The
hallmark gene sets were related to tumor immunology, cellular mitosis, EMT, adipose/stromal processes, and androgen signaling. The x-axis in each graph subdivides
(Continued)
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FIGURE 9 | the gene set expression in 4T1 compared to Py230 primary tumors at 1, 3, and 6w p.i. The y-axis in each graph indicates the score (corresponding with
the P-value in log10 scale) for the gene set expression in 4T1 compared to Py230 primary tumors. More specifically, a positive score identifies that the gene set is higher
expressed in 4T1 than in Py230 primary tumors, whereas a negative score identifies the opposite. The dashed lines indicate the minimal level of significance (= 0.05 or
1.3 in log10 scale) and allow to identify whether the difference in expression of the hallmark gene set between 4T1 and Py230 primary tumors is statistically significant.
FIGURE 10 | Differential expression of T-cell receptors in primary tumors of the 4T1- compared to Py230-based intraductal model. Heatmap displaying expression
levels of selected genes involved in co-stimulatory/co-inhibitory T-cell receptors in three independent 4T1 and Py230 primary tumor samples at 1w p.i. (A), 3w p.i.
(B), and 6w p.i. (C). (D) Heatmap displaying the log2 fold change in mean gene expression of the selected co-stimulatory/co-inhibitory T-cell receptors in 4T1 and
Py230 primary tumor samples at 1, 3, and 6w p.i. The selection of the T-cell receptor genes was based on the gene list from the NanoString Mouse PanCancer
Immune Profiling Panel and a publication by Yu et al. (30). Hierarchical clustering was performed using Pearson distance.
(Supplementary Figure 5), indicative for an active involution
process following lactation. The control samples did not show
upregulation of immunological hallmarks, which suggests that
the injection method and Matrigel R© have minimal influence on
tumor immunology.
Next, a specific gene set for co-stimulatory and co-inhibitory
T-cell receptors was investigated at 1, 3, and 6w p.i. in 4T1
and Py230 primary tumors. Individual heatmaps were generated
for the expression levels at each time point and every heatmap
indicated increased T-cell receptor expression in most, but not
all 4T1 compared to Py230 primary tumors (Figures 10A–C).
Yet, the difference in T-cell receptor gene expression between
the 4T1 and Py230 primary tumors decreased over time
(Figure 10D). Furthermore, gene sets for antigen presentation,
macrophage polarization and cytokines/cytokine receptors were
also investigated. Based on the heatmap, differential expression
of genes involved in antigen presentation strongly decreased at
6w p.i. in 4T1 compared to Py230 primary tumors (Figure 11A).
Gene expression data also showed that 4T1 primary tumors
change from an anti-inflammatory at 1w p.i. to a pro-
inflammatory macrophage gene signature at 6 w p.i. compared
to Py230 primary tumors (Figure 11B). This finding was further
supported by upregulation of pro- and downregulation of anti-
inflammatory cytokines and their receptors at 6 w p.i. in 4T1
compared to Py230 primary tumors (Figure 11C).
DISCUSSION
Inoculation of murine mammary tumor cells in the teat duct
is increasingly accepted as an alternative to the classical fat pad
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FIGURE 11 | Differential expression of antigen presentation, macrophage polarization and cytokines/cytokine receptor gene sets in primary tumors of the 4T1-
compared to Py230-based intraductal model. Heatmaps displaying the log2 fold change in mean gene expression of selected genes involved in antigen presentation,
macrophage polarization and cytokines/cytokine receptors in 4T1 and Py230 primary tumor samples at 1, 3, and 6w p.i. The selection of the genes was based on the
gene list from the NanoString Mouse PanCancer Immune Profiling Panel and a publication by Yu et al. (30). Genes that characterize pro-inflammatory and
anti-inflammatory macrophage polarization were selected based on a publication by Jablonski et al. (31). Hierarchical clustering was performed using Pearson
distance.
inoculation for studying breast cancer. The added value of such
intraductally established tumors is that they grow from within
the mammary ducts and first undergo ductal breakthrough prior
to their invasion of the mammary fat pad and their metastasis
to other organs, which more closely resembles the disease
process in humans (3–5). The use of fully immunocompetent
syngeneic mice further allows to study the influence of the
immune system, which has recently been recognized to play
a key role in mammary tumor progression (25, 26). In this
context, we have previously shown that macrophages are critical
regulators of the DCIS to IC progression and stimulate metastasis
in the 4T1-based syngeneic intraductal model for TNBC (4).
With the current comparative study, we aimed to gain deeper
insight in the immunological changes underlying aggressive
4T1 vs. non-aggressive Py230 intraductal tumor progression,
providing further characterization of the intraductal model
prior to its envisaged use for evaluation of novel breast
cancer therapeutics.
Following intraductal inoculation, 4T1 tumor cells initially
grew faster and showed earlier ductal breakthrough than Py230
tumor cells, reproducibly metastasizing to axillary lymph nodes,
lungs and livers at 6 w p.i., in marked contrast to the absence of
metastases in the Py230-based intraductal model. Although it was
not checked how long it takes for the Py230-based intraductal
model to induce detectable metastases, previous studies reported
that it may take up to 20 weeks for the development of Py230
lung metastases (14). Indeed, the Py230 tumor cell line is not
susceptible to EMT, being an important feature to gain migratory
and hence metastatic capacity (32, 33).
At 6w p.i., 4T1 and Py230 primary tumors had a similar size,
which could be explained by their marked difference in Ki67
positivity and Ki67 proliferation index, reflecting a decreased
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proliferation of 4T1 in time compared to Py230 primary tumors.
Indeed, 4T1 tumors are typically only highly proliferative at the
edges being a hallmark of their aggressive invasive and metastatic
character (34) while their core remains poorly proliferative due
to a lack of essential nutrients and oxygen (30). Our data further
demonstrated that Py230 tumors were able to catch up with
4T1 tumor growth by proliferating both at the tumor core and
the edges. Complementary RNA-seq analysis could attribute
this decreased proliferation of 4T1 compared to Py230 primary
tumors to the significant downregulation of genes involved in
cellular mitosis at 3 w p.i. At that time point, a significant
upregulation of genes involved in EMT and adipogenic/stromal
processes indicated that 4T1 cells focus on both EMT and
stromal development for metastasis rather than on primary
tumor growth compared to Py230 cells. The increased expression
of genes related to adipogenesis and stromal processes can also be
explained by the fact that both 4T1 and Py230 cells were injected
in actively involuting mammary glands. Lactation makes the teat
orifice accessible for intraductal inoculation without surgery or
microscopic guidance (3, 5). Moreover, it offers a representative
model for pregnancy-associated breast cancer, which is associated
with high mortality rates in young women and has remained
understudied till date (35, 36).
The aggressive metastatic progression of the 4T1-based
tumors was further associated with increased local and systemic
levels of MMP-9, an essential matrix degrading protein that paves
the way for invasion, and of VEGF, which is an important driver
of blood vessel development for sustaining oxygen and nutrient
supply and for transporting tumor cells to distant organs. Of
relevance, the kinetic variation of MMP-9 and VEGF levels in
their local fold inductions showed a remarkable resemblance
with the differential primary tumor growth between the TNBC
models and the RNA-seq data. Indeed, at 1 w p.i., when 4T1
primary tumors were significantly more proliferative than Py230
primary tumors and cellular mitosis hallmarks were significantly
increased in 4T1 compared to Py230 primary tumors, the MMP-
9 levels were also more induced, allowing the fast expansion
and ductal breakthrough of 4T1 tumor cells. However, at 3 w
p.i., 4T1 primary tumors had become more oriented toward
adipose/stromal processes, including angiogenesis, resulting in
a significant induction of VEGF. In line with these results,
the hallmark angiogenesis was most strongly and significantly
upregulated at 3w p.i. in 4T1 compared to Py230 primary
tumors, as shown in the RNA-seq data. At 6w p.i., local
MMP-9 was again more induced compared to VEGF, which
may correspond with enhanced matrix degradation to allow
metastatic progression. However, this late MMP-9 induction
was lower than the early one at 1w p.i., which may be due
to the similar tumor sizes and cellular mitosis at 6 w p.i. in
4T1- vs. Py230-based primary tumors. In marked contrast, the
VEGF induction at 6w p.i remained similar to that at 1 w
p.i., corroborating the 4T1- vs. the Py230-based primary tumor
RNA-seq data for the hallmark angiogenesis. The increased fold
induction of MMP-9 compared to VEGF at 6w p.i. in serum was
in line with the increased systemic disease at that endpoint in the
4T1- compared to the Py230-based TNBC model as also shown
by the enhanced metastasis and splenomegaly data.
Similar to VEGF levels, CD31 positivity identified enhanced
vascularity in the 4T1-based intraductal model. CAIX positivity
reflected the increased hypoxia in 4T1 primary tumors
corroborating the decreased proliferation in the 4T1 tumor
core, which the 4T1 tumor cells try to alleviate by stimulating
angiogenesis for enhanced oxygen and nutrient supply, and
by increasing CAIX production for pH regulation (19). An
alternative hypoxia biomarker is pimonidazole, which needs
to be injected 1–2 h before scarification of the tumor-bearing
mice and has been regarded as more superior because of
this exogenous use in contrast to the endogenously produced
CAIX (37, 38). Yet, several studies have reported a good
agreement and only minor variations between both these
hypoxia stainings on tumor sections from different cancer types,
including breast cancer (39). Upon side-by-side comparison of
CAIX and pimonidazole stainings on 4T1 tumor sections in our
group, we also observed similar patterns and tumor hypoxia
(data not shown). In marked contrast to 4T1 primary tumors,
Py230 tumors showed only limited CAIX and CD31 positivity,
indicative for a more oxygen-enriched and nutritious tumor
environment enhancing cell viability and proliferation both at
the tumor core and edges, stimulating a fast and controlled
tumor outgrowth. In line with our results, Yang et al. also
categorized 4T1 tumors as highly angiogenic and invasive, but
weakly proliferative compared to other mammary tumor cell
lines following orthotopic immunocompetent inoculation in the
mammary fat pad (40).
Progressing 4T1 tumors are associated with severe
splenomegaly due to granulocytic hyperplasia (20, 21). Our
results also showed how spleen sizes significantly increased
over time in the 4T1-based intraductal model, whereas in
the Py230-based intraductal model spleens remained almost
at a normal size, suggesting differential leukemoid reactions
in both models. CHI3L1 and LCN2, two immune-related
biomarkers used for monitoring intraductal tumor progression
(3, 4) and breast cancer patient prognosis (22–24), confirmed
the differential tumor progression and immunology with
differential levels in spleens, primary tumors and serum of
both models. Immunophenotyping identified an increase of
immune cells in the 4T1 and Py230 primary tumors that
corresponded to the ductal mammary tumor progression in
each intraductal model, corroborating previous studies that
associated immune cell infiltration with tumor cell invasion in
breast cancer (41, 42). Both the abundance, localization and type
of immune cell populations were further investigated through
immunohistochemistry. Most immune cells surrounded the
mammary tumors, including CD163+ TAMs. These TAMs
are one of the most abundant type of immune cells in 4T1
and Py230 primary tumors at 1 w p.i., corroborating previous
studies in mice and humans (30, 42) and highlighting their
involvement in DCIS to IC progression as shown recently by our
group (4). Others have also shown that macrophage depletion
reduces tumor growth and invasion at early stages (43–46).
Over time, more Ly6G+ TANs and CD3ε+ TILs were found
within the primary tumor mass. The role of these cell types
in DCIS to IC transition is not well-known, yet both pro- and
anti-tumor properties have been attributed to them (47–49).
Frontiers in Immunology | www.frontiersin.org 15 December 2019 | Volume 10 | Article 2928
Steenbrugge et al. Intraductal Tumor Progression and Immunology
CD11c+ TADCs were also increasingly found over time within
the tumor mass in both intraductal models and are important in
T-cell activation through their antigen presenting function. As
CD11c+ TADCs and TILs are strongly correlated in TNBC (50),
the increase in TADCs corroborates with an upregulation of
CD3ε+, CD8a+, and CD4+ cells in primary tumors. Moreover,
as both 4T1 and Py230 tumors were infiltrated with TILs, and
more specifically immunoreactive CD8a+ cytotoxic T-cells and
CD4+ T-helper cells, they can be classified as so called “hot”
tumors (51). Yet, FoxP3+ regulatory T-cells were upregulated in
Py230 compared to 4T1 primary tumors, highlighting a strongly
immunosuppressed and proliferative microenvironment in the
Py230-based model. The progressive NF-κB activation in Py230
primary tumors and draining axillary lymph nodes corroborated
the increases in tumor immune cell populations over time.
Cytokine profiles further corroborated the enhanced local
and systemic leukemoid responses in the 4T1- compared to
Py230-based intraductal model. More specifically, 4T1 primary
tumors showed a stimulated pro-inflammatory cytokine profile
including IL-1β, IL-6, IFN-γ, and TNF-α, suggesting a cytotoxic
immune microenvironment with T-cell activation. Although
increased TGF-β1 levels in the 4T1-based intraductal model
might indicate immunosuppression, they can also be attributed
to 4T1 tumor invasion (52). In marked contrast, Py230
primary tumors showed a stimulated anti-inflammatory cytokine
profile including increased IL-10 and IL-4 levels at all time
points, corroborating the enhanced regulatory T-cell positivity
and immunosuppressive properties of Py230 primary tumors.
Moreover, based on granzyme B and PD-1 positivity, 4T1
tumors showed significantly stronger activation of cytotoxic T-
cells compared to Py230 tumors, in line with the differential
cytokine profiles.
An important remaining question is what regulates and
determines the immunological differences between both
intraductal TNBC models. An important tumor cell extrinsic
factor that should not be neglected and could have influenced
the tumor immunology is the mouse strain-dependent immune
bias. Indeed, BALB/c mice are notoriously Th2 skewed and
produce potent antibody responses, which is one of the reasons
that this is the strain of choice for hybridoma production, allergy
studies and anti-parasite studies (30, 53–55). On the other hand,
C57BL/6 mice are much more Th1 prone, which is the reason
why this strain is frequently used for viral and tumor studies
(30, 53–55). Yet, the current study shows that C57BL/6-derived
Py230 primary tumors are more immunosuppressive compared
to BALB/c-derived 4T1 primary tumors, demonstrating that
tumor cell intrinsic or other extrinsic factors overruled the
strain-specific immunity in regulating the mammary tumor
immune responses and phenotype. Of note, other frequently
used C57BL/6-derived tumor cell lines are known to be highly
inflammatory compared to BALB/c-derived tumors (40, 56),
demonstrating that not every tumor in C57BL/6 mice is less
inflammatory and again suggesting that intrinsic/extrinsic factors
play a key role in shaping tumor immunity in mouse models. The
specific environment in which tumor cells grow can also highly
impact on the tumor immunology and immunotherapeutic
responses (30). To this end, orthotopic implantation of tumor
cells has been reported to establish a highly immunosuppressive
tumor phenotype that is less responsive to immunotherapy
compared to subcutaneously implanted tumors (30, 57). Since
the mammary ducts are considered as the truly orthotopic
injection site for mammary tumor cells (5, 8), the intraductal
model is most likely to resemble the correct immunophenotype
associated with implanted mammary tumor cell lines and also
mimic tumor immunology and therapeutic responses observed
in patients. Furthermore, it may be a concern that only 4T1
cells carried a luciferase reporter gene, which as a foreign gene
could influence the differential tumor immunology between the
4T1- and Py230-based intraductal model. However, previous
reports have shown that luciferase is a very weak antigen and
does not significantly alter tumor progression (58, 59). Moreover,
4T1 cells are also intrinsically weakly immunogenic and have a
limited mutational burden (40, 58).
Further corroborating the cytokine profiles and the reports
that T-cell activation may decrease tumor proliferation, RNA-
seq also identified increased tumor-associated immune responses
in 4T1 compared to Py230 primary tumors. However, there
was a decreasing trend over time in all immunology-related
gene sets, indicating that Py230 primary tumors were catching
up with 4T1 tumor immunology. This finding was also
highlighted by gene sets for T-cell receptors and antigen
presentation, showing a decrease over time in differential
gene expression between 4T1 and Py230 primary tumors.
Interestingly, CD274, also referred to as the immune checkpoint
protein programmed death-ligand 1 (PD-L1), was one of the
few genes that remained upregulated at 6w p.i. compared to
1w p.i., suggesting that the PD-L1 axis plays a critical role in
4T1 tumor progression. The latter increase in expression also
corroborates the increased protein levels of IFN-γ, an important
inducer for PD-L1 (60). Nevertheless, Mosely et al. reported
that anti-PD-L1 treatment of 4T1 tumors fails to induce an
effective therapeutic response (56). Upon further investigation
these authors identified that granulocytic myeloid-derived
suppressor cells (MDSCs) were present in high numbers in
these 4T1 primary tumors, highlighting excessive granulocytosis
in the 4T1-based intraductal model (56). The decreased
expression of anti-inflammatory and increased expression of
pro-inflammatory cytokines and macrophage markers over time
in 4T1 compared to Py230 primary tumors again confirmed
that Py230 tumors are highly immunosuppressed and likely will
be even more refractory to checkpoint inhibitors. It can be
suggested that in order to overcome immunosuppression and
allow effective immunotherapy in both intraductal models for
TNBC, an additional layer of treatment may be required, such
as chemotherapy, radiotherapy, agonists of T-cell co-stimulatory
receptors or vaccines (56, 61, 62). Alternatively, Li et al. recently
reported that TNBC can be eradicated by targeting glycosylated
PD-L1, inducing both immune re-activation as well as 4T1 tumor
cell killing (63). The current study also showed a remarkable
upregulation of genes related to androgen signaling in Py230
primary tumors, indicating that androgens play an important
role in intraductal Py230 tumor outgrowth (64). It can therefore
be suggested that inhibition of androgen receptor signaling
may provide a beneficial therapeutic effect in the Py230-based
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intraductal model for TNBC. Of relevance and in line with this
hypothesis, a subset of TNBC patients shows high expression of
the androgen receptor and remains difficult to treat, but shows
good responses to anti-androgen therapy (65).
Taken together, the 4T1- and Py230-based intraductal
model are characterized by a different tumor outgrowth and
associated tumor microenvironment. More specifically, whereas
4T1 tumors are aggressively metastatic and show high levels of
EMT, hypoxia and inflammation, Py230 tumors remain locally
invasive and show high proliferation and immunosuppression.
These differential models may broadly represent the clinically
observed TNBC diversity and together provide a powerful tool
to evaluate immunotherapy and therapeutic combinations in a
truly orthotopic environment at both early (DCIS) or late stage
(IC) breast carcinoma.
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Supplementary Figure 1 | In vivo imaging of 4T1 primary tumor progression and
identification of metastases in the 4T1- and Py230-based intraductal model. (A)
Representative image of the in vivo bioluminescence as a measurement of primary
tumor growth in 4T1 intraductally inoculated mice at 1, 3, and 6w p.i. (B) H&E
histology for the identification of metastases in axillary lymph nodes, lungs, and
liver from 4T1 and Py230 intraductally inoculated mice at 6w p.i. Dashed inserts
show a magnification of tumor tissue in the 4T1-based intraductal model and
normal tissue in the Py230-based intraductal model. White dashed lines in the
axillary lymph node image derived from the 4T1-based intraductal model indicate
the border between normal and tumor tissue. Black scale bar = 100µm; red scale
bar = 50µm. Representative images of ex vivo bioluminescence derived from 4T1
metastases at 6w p.i. in axillary lymph nodes, lungs, and liver are also shown.
Supplementary Figure 2 | Fold induction of MMP-9 and VEGF levels in the 4T1-
compared to Py230-based intraductal model. (A) Table showing the mean
MMP-9 and VEGF levels measured in primary tumors and serum of the 4T1- and
Py230-based intraductal model at 1, 3, and 6w p.i. as displayed in Figures 3A,B.
The relative fold induction of mean MMP-9 and VEGF levels at each time point in
4T1- compared to Py230-derived primary tumors and serum was calculated and
displayed in red. (B,C) Graphs displaying the calculated fold induction of mean
MMP-9 and VEGF levels at 1, 3, and 6w p.i. in primary tumors (B) and serum (C)
of the 4T1- compared to the Py230-based intraductal model.
Supplementary Figure 3 | Host NF-κB activity upon progression of intraductally
inoculated Py230 tumor cells in NF-κB reporter mice. (A) Representative image of
the in vivo bioluminescence as a measurement of host NF-κB activation in Py230
intraductally inoculated NF-κB reporter mice at 1, 3, and 6w p.i. (B) Host NF-κB
activation in Py230 primary tumors up to 6w p.i. based on weekly measurements
of the total flux density at the inoculation sites (n = 20 tumors at 1w p.i., n = 10
tumors at all other time points). (C) Representative image of the ex vivo
bioluminescence in axillary lymph nodes of Py230 intraductally inoculated NF-κB
reporter mice at 1, 3, and 6w p.i. (D) Host NF-κB activation in axillary lymph
nodes of Py230 intraductally inoculated NF-κB reporter mice at 1, 3, and 6w p.i.
based on measurements of the total flux density (n = 4 axillary lymph nodes at 1
and 3w p.i., n = 5 axillary lymph nodes at 6w p.i.). Data are presented as the
means ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Supplementary Figure 4 | Serum cytokine levels in the 4T1- compared to
Py230-based intraductal model and immunohistochemical analysis of activated
B-cells in 4T1 primary tumors. Cytokine levels at 1w p.i. (A), 3w p.i. (B), and 6w
p.i. (C) in serum of the 4T1- and Py230-based intraductal model (BAFF, G-CSF,
IFN-γ, IL-6, MCP-1, MIP-2, TNF-α: n = 5 at each time point and for both 4T1 and
Py230 sera; TGF-β1: n = 8 for 4T1 and n = 5 for Py230 at each time point). (D)
Immunohistochemistry for the activated B-cell marker CD19 on sections of 4T1
and Py230 primary tumors at 1, 3, and 6w p.i. (n = 5 at each time point for both
4T1 and Py230 primary tumors). Scale bar = 50µm. Data are presented as the
means ± SEM. NS, not significant. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
Supplementary Figure 5 | Heatmap related to the hallmarks identified in
Figure 9. The heatmap displays the expression of the hallmarks from Figure 9 in
4T1 and Py230 primary tumors and Matrigel®-only inoculated mammary glands at
1, 3, and 6w p.i. (n = 3 at each time point for 4T1 and Py230 primary tumors and
Matrigel®-only inoculated BALB/c- and C57BL/6-derived mammary glands).
Hierarchical clustering was performed using Euclidean distance.
REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal
A. Global cancer statistics 2018: GLOBOCAN estimates of
incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J Clin. (2018) 68:394–424. doi: 10.3322/caac.
21492
2. Spellman A, Tang SC. Immunotherapy for breast cancer: past,
present, and future. Cancer Metastasis Rev. (2016) 35:525–46.
doi: 10.1007/s10555–016-9654–9
Frontiers in Immunology | www.frontiersin.org 17 December 2019 | Volume 10 | Article 2928
Steenbrugge et al. Intraductal Tumor Progression and Immunology
3. Steenbrugge J, Breyne K, Denies S, Dekimpe M, Demeyere K, De Wever O,
et al. Comparison of the adipose and luminal mammary gland compartment
as orthotopic inoculation sites in a 4T1-based immunocompetent preclinical
model for triple-negative breast cancer. J Mammary Gland Biol Neoplasia.
(2016) 21:113–22. doi: 10.1007/s10911–016-9362–7
4. Steenbrugge J, Breyne K, Demeyere K, De Wever O, Sanders NN, Van
Den Broeck W, et al. Anti-inflammatory signaling by mammary tumor cells
mediates prometastatic macrophage polarization in an innovative intraductal
mouse model for triple-negative breast cancer. J Exp Clin Cancer Res. (2018)
37:191. doi: 10.1186/s13046–018-0860-x
5. Boiy R, Steenbrugge J, Van Deun J, Hendrix A, Meyer E, De Wever
O. Transparent reporting of experimental parameters in assays measuring
phenotypic steps in metastasis. Clin Exp Metastasis. (2018) 35:715–5.
doi: 10.1007/s10585–018-9944–4
6. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC,
et al. An intraductal human-in-mouse transplantation model mimics the
subtypes of ductal carcinoma in situ. Breast Cancer Res. (2009) 11:R66.
doi: 10.1186/bcr2358
7. Russell TD, Jindal S, Agunbiade S, Gao D, Troxell M, Borges
VF, et al. Myoepithelial cell differentiation markers in ductal
carcinoma in situ progression. Am J Pathol. (2015)185:3076–89.
doi: 10.1016/j.ajpath.2015.07.004
8. Sflomos G, Dormoy V, Metsalu T, Jeitziner R, Battista L, Scabia V, et al.
A preclinical model for ERα-positive breast cancer points to the epithelial
microenvironment as determinant of luminal phenotype and hormone
response. Cancer Cell. (2016) 29:407–22. doi: 10.1016/j.ccell.2016.02.002
9. Ghosh A, Sarkar S, Banerjee S, Behbod F, Tawfik O, McGregor D, et al.
MIND model for triple-negative breast cancer in syngeneic mice for quick
and sequential progression analysis of lung metastasis. PLoS ONE. (2018)
13:e0198143. doi: 10.1371/journal.pone.0198143
10. Atiya HI, Dvorkin-Gheva A, Hassell J, Patel S, Parker RL, Hartstone-Rose
A, et al. Intraductal adaptation of the 4T1 mouse model of breast cancer
reveals effects of the epithelial microenvironment on tumor progression and
Metastasis.Anticancer Res. (2019) 39:2277–87. doi: 10.21873/anticanres.13344
11. CarlsenH,Moskaug JO, FrommSH, Blomhoff R. In vivo imaging of NF-kappa
B activity. J Immunol. (2002) 168:1441–6. doi: 10.4049/jimmunol.168.3.1441
12. Tao K, FangM, Alroy J, Sahagian GG. Imagable 4T1model for the study of late
stage breast cancer. BMCCancer. (2008) 8:228. doi: 10.1186/1471–2407-8–228
13. Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S,
et al. A mouse model for triple-negative breast cancer tumor-initiating cells
(TNBC-TICs) exhibits similar aggressive phenotype to the human disease.
BMC Cancer. (2012) 12:120. doi: 10.1186/1471–2407-12–120
14. Bao L, Cardiff RD, Steinbach P, Messer KS, Ellies LG. Multipotent luminal
mammary cancer stem cells model tumor heterogeneity. Breast Cancer Res.
(2015) 17:137. doi: 10.1186/s13058–015-0615-y
15. Almeida JS, Iriabho EE, Gorrepati VL, Wilkinson SR, Gruneberg A, Robbins
DE, et al. ImageJS: personalized, participated, pervasive, and reproducible
image bioinformatics in the web browser. J Pathol Inform. (2012) 3:25.
doi: 10.4103/2153–3539.98813
16. Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F,
Harris AL, et al. Distinct molecular signature of inflammatory breast cancer
by cDNA microarray analysis. Breast Cancer Res Treat. (2005) 93:237–46.
doi: 10.1007/s10549–005-5157-z
17. Babicki S, Arndt D, Marcu A, Liang Y, Grant JR, Maciejewski A, et al.
Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. (2016)
44:W147–53. doi: 10.1093/nar/gkw419
18. Lou Y, Preobrazhenska O, auf dem Keller U, Sutcliffe M, Barclay L, McDonald
PC, et al. Epithelial-mesenchymal transition (EMT) is not sufficient for
spontaneous murine breast cancer metastasis. Dev Dyn. (2008) 237:2755–68.
doi: 10.1002/dvdy.21658
19. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, et al.
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis
by novel carbonic anhydrase IX inhibitors. Cancer Res. (2011) 71:3364–76.
doi: 10.1158/0008–5472.CAN-10–4261
20. DuPre SA, Hunter KW Jr. Murine mammary carcinoma 4T1
induces a leukemoid reaction with splenomegaly: association with
tumor-derived growth factors. Exp Mol Pathol. (2007) 82:12–24.
doi: 10.1016/j.yexmp.2006.06.007
21. Liu M, Jin X, He X, Pan L, Zhang X, Zhao Y. Macrophages support splenic
erythropoiesis in 4T1 tumor-bearing mice. PLoS ONE. (2015) 10:e0121921.
doi: 10.1371/journal.pone.0121921
22. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new
prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev.
(2006) 15:194–202. doi: 10.1158/1055–9965.EPI-05–0011
23. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A.
Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor
prognosis in human primary breast cancer. Breast Cancer Res Treat. (2008)
108:389–97. doi: 10.1007/s10549–007-9619–3
24. Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis
E, et al. Circulating levels of matrix metalloproteinase-9 (MMP-9),
neutrophil gelatinase-associated lipocalin (NGAL) and their complex
MMP-9/NGAL in breast cancer disease. BMC Cancer. (2009) 9:390.
doi: 10.1186/1471–2407-9–390
25. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and
metastasis. Nat Med. (2013) 19:1423–37. doi: 10.1038/nm.3394
26. Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al.
Understanding the tumor immune microenvironment (TIME) for effective
therapy. Nat Med. (2018) 24:541–50. doi: 10.1038/s41591–018-0014-x
27. Taniguchi K, Karin M. NF- κB, inflammation, immunity and cancer: coming
of age. Nat Rev Immunol. (2018) 18:309–24. doi: 10.1038/nri.2017.142
28. Notebaert S, Carlsen H, Janssen D, Vandenabeele P, Blomhoff R, Meyer
E. In vivo imaging of NF-kappaB activity during Escherichia coli-
induced mammary gland infection. Cell Microbiol. (2008) 10:1249–58.
doi: 10.1111/j.1462–5822.2008.01123.x
29. Breyne K, Cool SK, Demon D, Demeyere K, Vandenberghe T, Vandenabeele P,
et al. Non-classical proIL-1beta activation during mammary gland infection
is pathogen-dependent but caspase-1 independent. PLoS ONE. (2014)
9:e105680. doi: 10.1371/journal.pone.0105680
30. Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S,
et al. Tumor-immune profiling of murine syngeneic tumor models as
a framework to guide mechanistic studies and predict therapy response
in distinct tumor microenvironments. PLoS ONE. (2018) 13:e0206223.
doi: 10.1371/journal.pone.0206223
31. Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich
PG, Partida-Sanchez S, et al. Novel markers to delineate murine
M1 and M2 macrophages. PLoS ONE. (2015) 10:e0145342.
doi: 10.1371/journal.pone.0145342
32. Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev
Pathol. (2018) 13:395–412. doi: 10.1146/annurev-pathol-020117–043854
33. Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and
metastasis. Dev Cell. (2019) 49:361–74. doi: 10.1016/j.devcel.2019.04.010
34. Pulaski B.A., Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr
Protoc Immunol. (2001) 20:2. doi: 10.1002/0471142735.im2002s39
35. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev
Cancer. (2006) 6:281–91. doi: 10.1038/nrc1839
36. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W,
et al. Remodeling of the mammary microenvironment after lactation
promotes breast tumor cell metastasis. Am J Pathol. (2006) 168:608–20.
doi: 10.2353/ajpath.2006.050677
37. Aguilera KY, Brekken RA. Hypoxia Studies with Pimonidazole in vivo. Bio
Protoc. (2014) 4:e1254. doi: 10.21769/BioProtoc.1254
38. Bao B, Groves K, Zhang J, Handy E, Kennedy P, Cuneo G, et al. In vivo
imaging and quantification of carbonic anhydrase IX expression as an
endogenous biomarker of tumor hypoxia. PLoS ONE. (2012) 7:e50860.
doi: 10.1371/journal.pone.0050860
39. Tafreshi NK, Lloyd MC, Proemsey JB, Bui MM, Kim J, Gillies RJ, et al.
Evaluation of CAIX and CAXII expression in breast cancer at varied O2 levels:
CAIX is the superior surrogate imaging biomarker of tumor hypoxia. Mol
Imaging Biol. (2016) 18:219–31. doi: 10.1007/s11307–015-0885-x
40. Yang Y, Yang HH, Hu Y, Watson PH, Liu H, Geiger TR, et al.
Immunocompetent mouse allograft models for development of therapies
to target breast cancer metastasis. Oncotarget. (2017) 8:30621–43.
doi: 10.18632/oncotarget.15695
41. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte
composition of human breast cancer. Proc Natl Acad Sci USA. (2012)
109:2796–801. doi: 10.1073/pnas.1104303108
Frontiers in Immunology | www.frontiersin.org 18 December 2019 | Volume 10 | Article 2928
Steenbrugge et al. Intraductal Tumor Progression and Immunology
42. Gil Del Alcazar CR, Huh SJ, EkramMB, Trinh A, Liu LL, Beca F, et al. Immune
escape in breast cancer during in situ to invasive carcinoma transition. Cancer
Discov. (2017) 7:1098–115. doi: 10.1158/2159–8290.CD-17–0222
43. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1
promotes progression of mammary tumors to malignancy. J Exp Med. (2001)
193:727–40. doi: 10.1084/jem.193.6.727
44. Rumney RMH, Coffelt SB, Neale TA, Dhayade S, Tozer GM, Miller G. PyMT-
Maclow: a novel, inducible, murine model for determining the role of CD68
positive cells in breast tumor development. PLoS ONE. (2017) 12:e0188591.
doi: 10.1371/journal.pone.0188591
45. Carron EC, Homra S, Rosenberg J, Coffelt SB, Kittrell F, Zhang
Y, et al. Macrophages promote the progression of premalignant
mammary lesions to invasive cancer. Oncotarget. (2017) 8:50731–46.
doi: 10.18632/oncotarget.14913
46. Linde N, Casanova-Acebes M, Sosa MS, Mortha A, Rahman A, Farias E, et al.
Macrophages orchestrate breast cancer early dissemination and metastasis.
Nat Commun. (2018) 9:21. doi: 10.1038/s41467–017-02481–5
47. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor
and antitumor immunity. Curr Opin Genet Dev. (2008) 18:11–8.
doi: 10.1016/j.gde.2007.12.007
48. Uribe-Querol E, Rosales C. Neutrophils in cancer: two sides of the same coin.
J Immunol Res. (2015) 2015:983698. doi: 10.1155/2015/983698
49. Nelson AC, Machado HL, Schwertfeger KL. Breaking through to the
other side: microenvironment contributions to DCIS initiation and
progression. J Mammary Gland Biol Neoplasia. (2018) 23:207–21.
doi: 10.1007/s10911–018-9409-z
50. Lee H, Lee HJ, Song IH, Bang WS, Heo SH, Gong G, et al. CD11c-positive
dendritic cells in triple-negative breast cancer. In vivo. (2018) 32:1561–9.
doi: 10.21873/invivo.11415
51. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune
set point. Nature. (2017) 541:321–30. doi: 10.1038/nature21349
52. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga
CL, et al. Invasion and metastasis of a mammary tumor involves
TGF-beta signaling. Int J Cancer. (2001) 91:76–82. doi: 10.1002/1097--
0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2--8
53. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune
response in Th1- and Th2-dominant mouse strains. Shock. (2004) 22:460–6.
doi: 10.1097/01.shk.0000142249.08135.e9
54. Yagi J, Arimura Y, Takatori H, Nakajima H, Iwamoto I, Uchiyama T. Genetic
background influences Th cell differentiation by controlling the capacity for
IL-2-induced IL-4 production by naive CD4+ T cells. Int Immunol. (2006)
18:1681–90. doi: 10.1093/intimm/dxl102
55. Trunova GV, Makarova OV, Diatroptov ME, Bogdanova IM, Mikchailova
LP, Abdulaeva SO. Morphofunctional characteristic of the immune system
in BALB/c and C57BL/6 mice. Bull Exp Biol Med. (2011) 151:99–102.
doi: 10.1007/s10517–011-1268–1
56. Mosely SI, Prime JE, Sainson RC, Koopmann JO, Wang DY, Greenawalt
DM, et al. Rational selection of syngeneic preclinical tumor models for
immunotherapeutic drug discovery. Cancer Immunol Res. (2017) 5:29–41.
doi: 10.1158/2326–6066.CIR-16–0114
57. Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP,
et al. Tissues in different anatomical sites can sculpt and vary the tumor
microenvironment to affect responses to therapy.Mol Ther. (2014) 22:18–27.
doi: 10.1038/mt.2013.219
58. Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Interleukin-
12 gene therapy of a weakly immunogenic mouse mammary carcinoma
results in reduction of spontaneous lung metastases via a T-cell-independent
mechanism. Cancer Gene Ther. (2000) 7:826–38. doi: 10.1038/sj.cgt.7700176
59. Petkov SP, Heuts F, Krotova OA, Kilpelainen A, Engstrom G, Starodubova
ES, et al. Evaluation of immunogen delivery by DNA immunization using
non-invasive bioluminescence imaging. Hum Vaccin Immunother. (2013)
9:2228–36. doi: 10.4161/hv.25561
60. Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual
faces of IFNγ in cancer progression: a role of PD-L1 induction in the
determination of pro- and antitumor immunity. Clin Cancer Res. (2016)
22:2329–34. doi: 10.1158/1078–0432.CCR-16–0224
61. Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy:
mounting an effective antitumor response and mechanisms of resistance.
Trends Cancer. (2015) 1:66–75. doi: 10.1016/j.trecan.2015.07.008
62. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church
CH, et al. Immunogenicity of murine solid tumor models as a defining feature
of in vivo behavior and response to immunotherapy. J Immunother. (2013)
36:477–89. doi: 10.1097/01.cji.0000436722.46675.4a
63. Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of
triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer
Cell. (2018) 33:187–201 e10. doi: 10.1016/j.ccell.2018.01.009
64. Giovannelli P, Di Donato M, Auricchio F, Castoria G, Migliaccio A.
Androgens induce invasiveness of triple negative breast cancer cells
through AR/Src/PI3-K complex assembly. Sci Rep. (2019) 9:4490.
doi: 10.1038/s41598–019-41016–4
65. Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo
S, et al. Androgen receptor in triple negative breast cancer: a potential
target for the targetless subtype. Cancer Treat Rev. (2018) 68:102–10.
doi: 10.1016/j.ctrv.2018.06.005
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Steenbrugge, Vander Elst, Demeyere, De Wever, Sanders, Van
Den Broeck, Dirix, Van Laere and Meyer. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org 19 December 2019 | Volume 10 | Article 2928
